We’re a clinical‑stage company pioneering tablet format peptide and protein replacement therapies that could redefine the standard of care for conditions with major unmet needs.
We leverage our N-Tab® platform, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream.
EB613 (oral PTH(1-34)) is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34), teriparatide tablet treatment to support earlier osteoanabolic intervention for postmenopausal women with osteoporosis at high risk for fracture.
We are developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP-2 peptide tablet for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health.
Bringing together scientific excellence and drug development expertise to deliver breakthrough oral therapies
In vitae orci fringilla, dignissim nulla quis, faucibus turpis. In vitae ex sapien. Suspendisse pretium porttitor tellus ac convallis.
